Skip to main content

RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)

Oct 22, 2021 12:50 am

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

  1. In PsA trials, over time the (ACR20) placebo response has increased (15% every 5 yrs)but was not associated with the active treatment effect size. 42 RCTs, the pooled placebo response was 20.3%; pooled treatment effect vs placebo was 27% https://t.co/b9LRpvcTir

  2. Propensity matched comparison of Tramadol vs Codeine use. Tramadol had a signif. higher risk of all-cause mortality (HR, 2.31), CV events (HR 1.15) & fractures (HR 1.50), but no diff in falls, delirium, constipation, opioid abuse, sleep disorders. https://bit.ly/2ZiocGz

  3. In a real world study of lupus patients, aspirin use lowered risk of preeclampsia, as did hydroxychloroquine. Risk Factors for preeclampsia were high Dz activity 1st trimester (OR 4.55), BMI >30 (6.14), antiphospholipid synd (8.02), hx preeclampsia (9.8) https://t.co/giBamMAPRM

  4. RECOVERY study of hospitalized COVID-19 pts compared colchicine to PBO (+usual care). Colchicine had no effect on 28d mortality (21% vs 21%), time to D/C(10 d vs 10d), LIve D/C (70 vs 70%), mechanical vent or death (25 vs 25%) https://bit.ly/2ZfNG7m

  5. JAMA reports the COVID-19 combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% By May 2021, there were 2.1 SARS-CoV-2 infections per reported COVID-19 case. https://t.co/bUZ5AqYnxM

  6. PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 15% UST vs 19% TNFi and Minimal Dz Activity was 26% UST vs 31% TNFi at 6 months - both were equipotent in PsA  https://t.co/RLadZa6YTI

  7. FDA Approves Cyltezo (BI), the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU

  8. Smoking Impairs Methotrexate Efficacy 

  9. TICOSPA - Does Treat to Target Work in Spondyloarthritis?

  10. NOBILITY: a Trial of Obinutuzumab in Proliferative Lupus Nephritis 

Disclosures
The author has received compensation as an advisor or consultant on this subject

Rheumatologists’ Comments

Dear Dr Cush - Great podcast as always - but one remark- it seems to me that aspirin can be taken up to delivery time - no worries about ductus arteriosous- that is what the APS experts sustain. All the best Eduardo Paiva MD FACR Curitiba Brazil

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×